Skip to main content

Table 2 Comparison of cumulative dose of anticancer drug (mg/body)

From: Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study

 

r+0.4<, N = 49

r+0.4≧, N = 41

P a)

CBDCA

3200 (2410, 3,877)

2500 (2000, 3,360)

0.10

PEM

9100 (6365, 11,260)

5600 (4140, 7,440)

< 0.01

BEV

8250 (4790, 12,000)

5510 (4020, 7,865)

0.07

  1. Median (interquartile range)
  2. CBDCA carboplatin, PEM pemetrexed, BEV bevacizumab
  3. a)Mann-Whitney U test
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us